SelvitaS.A.
Research and experimental development in natural sciences and engineering
Overview
Selvita is an integrated service provider specializing in drug discovery and drug development. It offers comprehensive services from target validation to preclinical candidate nomination, supporting small molecules, antibodies, and protein degraders, along with extensive drug development and regulatory support for both small and large molecules. The company adheres to GMP and GLP regulations, ensuring scientific consistency and global compliance throughout the development process.
Financials
The financial statement for 2024 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 21.35
- High
- PLN 22.45
- Low
- PLN 21.35
- Volume
- 10.91K
- Avg. vol.
- 35.69K
- Market cap
- PLN 401.98M
- P/E ratio
- —
- EPS
- -PLN 0.11
- Shares outstanding
- 18.36M
- 52-week
- PLN 20.20 – 23.60
- Dividend yield
- —
- Dividend
- —
- Ex dividend date
- —
- ISIN
- PLSLVCR00029
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 22.19m | USD -183.95k | USD -821.45k |
| Q1 2026 | USD 20.52m | USD -482.44k | USD -1.47m |
| Q4 2025 | USD 23.26m | USD 2.11m | USD 1.84m |
| Q3 2025 | USD 22.12m | USD 572.58k | USD -235.06k |
Results for Q3 2026:Nov 19, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2019-08-09. Active
96 1240 2294 1111 0011 6488 4813- 84 1240 2294 1111 0011 6681 2225
- 19 1240 6292 1784 0011 0150 2099
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
6 notices recorded in the Court and Commercial Gazette (MSiG).
| Publication date | Event | |
|---|---|---|
| Jun 2, 2020 | Commercial Companies Code notice | |
| Jun 2, 2020 | Commercial Companies Code notice | |
| Oct 14, 2019 | Merger registered | |
| Oct 14, 2019 | Call to creditors | |
| Jul 24, 2019 | Merger registered |
Public aid
19 public aid cases recorded, with a total value of $45,055,001.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 27, 2026 | Regional investment aid | — | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Mar 27, 2026 | Aid for research and development projects: industrial research | — | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Mar 27, 2026 | Aid for research and development projects: experimental development | — | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
8 projects co-financed from European Funds recorded, with total EU co-financing of $35,260,216.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2026-01-01 | Opracowanie technologii DRUG-PREDICT do przedklinicznej predykcji efektywności klinicznej związków biologicznie aktywnych w indykacji nowotworów jelita grubego i trzustki, opartej o translacyjne modele przedkliniczne in vitro i in vivo wspomagane narzędziem ML umożliwiającej identyfikację najlepszych innowacyjnych kandydatów na lek i optymalnych grup pacjentów | $3,490,265 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2026-01-01 | Zaawansowana platforma E3Explorer produkcji białek ligaz E3 wraz z charakteryzacją jako podstawa innowacyjnych terapii celowanych PROTAC | $2,325,809 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2025-10-01 | Platforma CART-AI do rozwoju zaawansowanych terapii immunoonkologicznych opartych na modyfikowanych limfocytach T z użyciem AI - etap przedkliniczny | $2,519,767 | Fundusze Europejskie dla Nowoczesnej Gospodarki |
Tenders
1 tender recorded as contractor, with a total value of $13,687.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Apr 7, 2025 | 459.2024 Wyłonienie wykonawcy na konsultacje treści sylabusów dla Wydziału Chemii w podziale na sześć części. | $13,687 | Uniwersytet Jagielloński |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | Waste generation | Active |
Authorized Representatives
Manner of representation
In the case of a multi-member management board, the company may be represented by two members of the management board acting jointly, or by a member of the management board acting jointly with one of the joint commercial proxies.
Supervisory board
Beneficial owners
No beneficial owners recorded for the company Selvita.
Subsidiaries
| Name | Share value | Stake | |
|---|---|---|---|
Selvita Servicessp. z o.o. | 78,336.03 USD | 100% | |
Pozlabsp. z o.o. | 3,336.03 USD | 100% |
Capital group
| Name | Ownership |
|---|---|
Aktywa netto p rzypadające n a Selvita S.A  | 74% |
Selvita Inc | 100% |
Selvita Ltd | 100% |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| KCRS.A. | $43,596,034.97 | kcrcro.com | |
| Polpharma BiologicsS.A. | $19,057,541.37 | polpharmabiologics.com | |
| InventionbioS.A. | $17,762,977.76 | inventionbio.pl | |
| Ryvu TherapeuticsS.A. | $15,633,852.34 | ryvu.com |
Change history
| Date | Event |
|---|---|
| 2023-05-31 | Address change (Ul. Profesora Michała Bobrzyńskiego 14, 30-348, Kraków → Ul. Podole 79, 30-394, Kraków) |
| 2020-06-18 | Share capital change (12,776,983.20 PLN → 14,684,379.20 PLN) |
| 2020-02-14 | Share capital change (12,876,983.20 PLN → 12,776,983.20 PLN) |
| 2019-10-01 | Share capital change (100,000.00 PLN → 12,876,983.20 PLN) |
| 2019-10-01 | Name change (Selvita Cro → Selvita) |
FAQ
Last updated: 2026-09-24